Community-Acquired Pneumonia | NEJM Skip to main content NEJM Group Follow Us
Facebook Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your …

Globally, pneumonia is a serious public health concern and a major cause of mortality and
morbidity. Despite advances in antimicrobial therapies, microbiological diagnostic tests and …

Background Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal
disease in infants, but their efficacy against pneumococcal community-acquired pneumonia …

To overview the present global burden of pneumococcal disease is important because new
preventive measures such as the pneumococcal conjugate vaccine 13 are currently being …

Background Routine vaccination of elderly people against pneumococcal diseases is
recommended in many countries. National guidelines differ, recommending either the 23 …

Before 1945, Streptococcus pneumoniae caused more than 90% of cases of pneumonia in
adults. After 1950, the proportion of pneumonia caused by pneumococcus began to decline …

The purpose of this paper was to generate up-to-date information on the aetiology of
community-acquired pneumonia (CAP) and its antibiotic management in adults across …

Pneumococcal (PC) vaccination is recommended for patients with chronic lymphocytic
leukemia (CLL). However, response to vaccines has been investigated in a small series of …

Pneumococcal polysaccharide vaccines (PPVs) and conjugate vaccines (PCVs), of which
PPV23 and PCV13 are the current front runners, have had a significant, beneficial impact on …

Objective A systematic review and meta-analysis to estimate the magnitude of the
association between alcohol consumption and the risk of community-acquired pneumonia …